LAMBDAVISION INCORPORATED — Department of Health and Human Services STTR Phase I: DESCRIPTION (provided by applicant): A flexible, protein-based, ion-mediated retinal impla
LAMBDAVISION INCORPORATED — STTR Phase I award from Department of Health and Human Services.
Phase I STTR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $190,499. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Amount
- $190,499
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Solicitation
- PA13-235
- NAICS
- —
- Place of performance
- CT
- Period
- —
Description
DESCRIPTION (provided by applicant): A flexible, protein-based, ion-mediated retinal implant is proposed for the restoration of vision for patients with retinal degenerative diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa(RP). The implant under development uses the retinal- containing protein, bacteriorhodopsin (BR), to convert light into a pH gradient. This gradient is capable of activating the neural circuitry of the retina, specificall the bipolar and ganglion cells. Bacteriorhodopsin is a light-driven proton pump isolated from a salt-marsh archaeon and this protein has a quantum efficiency nearly identical to rhodopsin, the protein in the rod outer segments of the eye. The high thermal and photochemical stability of BRmake it an excellent candidate for use as the photoactive medium in a protein-based retinal implant. The implant will operate by using a local pH gradient to activate the neural circuitry of the retina by decreasing the pH in the milieu surrounding th